Hydrogen Gas Shows Promise for Brain Protection in Schizophrenia Study
- Authors
- Nobumi Miyake, Toshiaki Haga, Shin-Ichi Hirano, Yusuke Ichikawa, Yoshiyo Oguchi, Kumiko Ando
- Journal
- Neuropsychopharmacology Reports
- Year
- 2026
- DOI
- 10.1002/npr2.70117
- Study Type
- Mouse
- Outcome
- Positive
- Peer Reviewed
- Yes
- Country
- Japan
- Health Condition
- Schizophrenia
- Body System
- Nervous System
TL;DR
Hydrogen gas inhalation restored hydroxyl radical antioxidant capacity in an MK-801-induced schizophrenia-like mouse model but did not significantly improve hyperactivity or cognitive-related behavioral outcomes.
Key Finding
Hydrogen gas inhalation restored antioxidant capacity in the brains of mice with schizophrenia-like symptoms, but did not significantly improve their behavioral abnormalities like hyperactivity or cognitive dysfunction.
Summary
Researchers tested whether inhaling hydrogen gas could help mice with schizophrenia-like symptoms caused by a drug called MK-801. The mice that received hydrogen gas showed improved antioxidant markers in their brains (meaning less cellular damage from harmful molecules), but their behavioral problems—like hyperactivity and cognitive issues—did not improve. This suggests hydrogen gas may have some protective effects on brain chemistry, but it didn't fix the behavioral symptoms in this mouse model.
Practical Takeaway
This is an early-stage animal study only, so findings cannot be applied to humans yet. While the results suggest hydrogen gas may have antioxidant effects in the brain, the fact that it didn't improve actual symptoms in mice raises questions about its practical benefit. Much more research, including human clinical trials, would be needed before any conclusions about hydrogen water's usefulness for schizophrenia could be drawn.
Abstract
Aims: Oxidative stress has recently emerged as a key factor in the pathophysiology of schizophrenia. This study investigated whether inhalation therapy with hydrogen gas, a selective antioxidant, could reduce oxidative stress and improve behavioral outcomes in an MK-801-induced schizophrenia-like mouse model. Methods: Six-week-old male C57BL/6 mice received chronic intraperitoneal injections of MK-801 (0.5 mg/kg) or saline for 4 weeks. A third group received MK-801 followed by hydrogen gas inhalation therapy. Behavioral assessments included the open-field test (OFT) to evaluate hyperactivity as an indicator of positive symptoms and the prepulse inhibition (PPI) test to assess cognitive dysfunction. Oxidative stress was evaluated by measuring whole-brain hydroxyl radical antioxidant capacity (HORAC) and total antioxidant capacity (TAC). Results: MK-801-treated mice exhibited significant hyperactivity in the OFT and a trend toward impaired PPI, confirming the schizophrenia-like phenotype. Hydrogen gas treatment did not produce significant improvements. MK-801 administration significantly reduced HORAC levels, whereas hydrogen gas therapy markedly restored them. No significant differences in TAC were observed among the groups. Conclusion: These findings suggest that hydrogen gas therapy does not significantly ameliorate behavioral abnormalities in the MK-801-induced schizophrenia-like mouse model but exerts beneficial antioxidant effects. Future studies should evaluate hydrogen gas as an adjunctive therapy and further assess its efficacy and safety in clinical settings.